K L Cheung1, N A Zakai1, P W Callas2, G Howard3, B K Mahmoodi4, C A Peralta5, S E Judd3, M Kurella Tamura6,7, M Cushman1. 1. Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 2. University of Vermont, Burlington, VT, USA. 3. University of Alabama Birmingham, Birmingham, AL, USA. 4. University of Groningen, Groningen, The Netherlands. 5. University of California San Francisco, San Francisco, CA, USA. 6. Stanford University, Stanford, CA, USA. 7. VA Palo Alto Health Care System, Palo Alto, CA, USA.
Abstract
Essentials Chronic kidney disease (CKD) is associated with procoagulant and inflammatory biomarkers. We studied the association of CKD and venous thromboembolism (VTE) in a case-cohort study. Factor VIII, D-dimer and C-reactive protein appeared to explain the association of CKD and VTE. Statin use was protective against VTE in those with and without CKD. SUMMARY: Background Chronic kidney disease (CKD) is associated with venous thromboembolism (VTE) risk via unknown mechanisms. Whether factors associated with reduced VTE risk in the general population might also be associated with reduced VTE risk in CKD patients is unknown. Objectives To determine whether thrombosis biomarkers attenuate VTE risk, and whether factors associated with reduced VTE risk are similarly effective in CKD patients. Methods Baseline biomarkers were measured in a cohort (294 VTE cases; 939 non-cases) from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a nationwide prospective cohort study of 30 239 persons aged ≥45 years with 4.3 years of follow-up. The hazard ratio (HR) of VTE per 10 mL min-1 1.73 m-2 decrease in estimated glomerular filtration rate (eGFR), and the percentage attenuation of this HR by each biomarker, were calculated. Associations of protective factors (physical activity, lower body mass index [BMI], and aspirin, warfarin and statin use) with VTE were estimated in those with and without CKD. Results The HR for VTE with lower eGFR was 1.13 (95% confidence interval [CI] 1.02-1.25), and VTE risk was attenuated by 23% (95% CI 5-100) by D-dimer, by 100% (95% CI 50-100) by factor VIII, and by 15% (95% CI 2-84) by C-reactive protein. Normal BMI was associated with lower VTE risk in those without CKD (HR 0.47, 95% CI 0.32-0.70), but not in those with CKD (HR 1.07, 95% CI 0.51-2.22). Statin use, physical activity and warfarin use were associated with lower VTE risk in both groups. Conclusions Procoagulant and inflammatory biomarkers mediated the association of eGFR with VTE. Higher physical activity, statin use and warfarin use mitigated VTE risk in those with CKD and those without CKD, but normal BMI did not mitigate VTE risk in CKD patients.
EssentialsChronic kidney disease (CKD) is associated with procoagulant and inflammatory biomarkers. We studied the association of CKD and venous thromboembolism (VTE) in a case-cohort study. Factor VIII, D-dimer and C-reactive protein appeared to explain the association of CKD and VTE. Statin use was protective against VTE in those with and without CKD. SUMMARY: Background Chronic kidney disease (CKD) is associated with venous thromboembolism (VTE) risk via unknown mechanisms. Whether factors associated with reduced VTE risk in the general population might also be associated with reduced VTE risk in CKDpatients is unknown. Objectives To determine whether thrombosis biomarkers attenuate VTE risk, and whether factors associated with reduced VTE risk are similarly effective in CKDpatients. Methods Baseline biomarkers were measured in a cohort (294 VTE cases; 939 non-cases) from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a nationwide prospective cohort study of 30 239 persons aged ≥45 years with 4.3 years of follow-up. The hazard ratio (HR) of VTE per 10 mL min-1 1.73 m-2 decrease in estimated glomerular filtration rate (eGFR), and the percentage attenuation of this HR by each biomarker, were calculated. Associations of protective factors (physical activity, lower body mass index [BMI], and aspirin, warfarin and statin use) with VTE were estimated in those with and without CKD. Results The HR for VTE with lower eGFR was 1.13 (95% confidence interval [CI] 1.02-1.25), and VTE risk was attenuated by 23% (95% CI 5-100) by D-dimer, by 100% (95% CI 50-100) by factor VIII, and by 15% (95% CI 2-84) by C-reactive protein. Normal BMI was associated with lower VTE risk in those without CKD (HR 0.47, 95% CI 0.32-0.70), but not in those with CKD (HR 1.07, 95% CI 0.51-2.22). Statin use, physical activity and warfarin use were associated with lower VTE risk in both groups. Conclusions Procoagulant and inflammatory biomarkers mediated the association of eGFR with VTE. Higher physical activity, statin use and warfarin use mitigated VTE risk in those with CKD and those without CKD, but normal BMI did not mitigate VTE risk in CKDpatients.
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Amirhossein Sahebkar; Corina Serban; Dimitri P Mikhailidis; Anetta Undas; Gregory Y H Lip; Paul Muntner; Vera Bittner; Kausik K Ray; Gerald F Watts; G Kees Hovingh; Jacek Rysz; John J P Kastelein; Maciej Banach Journal: Thromb Haemost Date: 2015-05-28 Impact factor: 5.249
Authors: Sarah R Gillett; Rebekah H Boyle; Neil A Zakai; Leslie A McClure; Nancy S Jenny; Mary Cushman Journal: Clin Biochem Date: 2014-08-14 Impact factor: 3.281
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Myriam Fornage; Rulan S Parekh; Josef Coresh; Wen Hong Linda Kao Journal: Clin J Am Soc Nephrol Date: 2015-04-17 Impact factor: 8.237
Authors: A Tosetto; A Iorio; M Marcucci; T Baglin; M Cushman; S Eichinger; G Palareti; D Poli; R C Tait; J Douketis Journal: J Thromb Haemost Date: 2012-06 Impact factor: 5.824
Authors: B Payson Oberg; Elizabeth McMenamin; F Lee Lucas; Ellen McMonagle; Jason Morrow; T Alp Ikizler; Jonathan Himmelfarb Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Lori D Bash; Thomas P Erlinger; Josef Coresh; Jane Marsh-Manzi; Aaron R Folsom; Brad C Astor Journal: Am J Kidney Dis Date: 2008-12-24 Impact factor: 8.860
Authors: Mary Cushman; Aaron R Folsom; Lu Wang; Nena Aleksic; Wayne D Rosamond; Russell P Tracy; Susan R Heckbert Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: Jade S Hiramoto; Ronit Katz; Carmen A Peralta; Joachim H Ix; Linda Fried; Mary Cushman; David Siscovick; Walter Palmas; Mark Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2012-05-04 Impact factor: 8.860
Authors: Vincent Ten Cate; Markus Nagler; Marina Panova-Noeva; Lisa Eggebrecht; Natalie Arnold; Heidrun Lamparter; M Iris Hermanns; Hugo Ten Cate; Martin H Prins; Christine Espinola-Klein; Thomas Münzel; Karl J Lackner; Philipp S Wild; Jürgen H Prochaska Journal: Haematologica Date: 2019-03-14 Impact factor: 9.941
Authors: D Leann Long; Boyi Guo; Leslie A McClure; Byron C Jaeger; Stephanie E Tison; George Howard; Suzanne E Judd; Virginia J Howard; Timothy B Plante; Neil A Zakai; Insu Koh; Katharine L Cheung; Mary Cushman Journal: Ann Epidemiol Date: 2021-11-03 Impact factor: 3.797